Pharmaceutical Patents

On June 5, 1972, Felix Theeuwes and Takeru Higuchi at Alza Corporation in Palo Alto, California co-filed 'Osmotic dispensing device for releasing beneficial agent' in the United States. It was granted as US3845770A on November 5, 1974. Claim 1 fences an osmotic device whose semipermeable wall holds the drug inside while allowing external fluid to enter — internal pressure rises by osmotic gradient, and the drug is pushed out at a constant rate through a laser-drilled orifice (described in the specification, not in Claim 1). On this patent's extension stand blockbuster controlled-release tablets such as Concerta (methylphenidate, ADHD), Procardia XL (nifedipine, hypertension), and Glucotrol XL (glipizide, diabetes). The DB consensus 'sole inventor Theeuwes' is **incorrect**: the patent's inventor field lists Theeuwes and Takeru Higuchi as **co-inventors** (Higuchi was a central figure in pharmacokinetics at the University of Kansas Pharmacy School, and was also involved as a consultant to Alza founder Alejandro Zaffaroni). This memo confirms the primary-source URL and Claim 1 — full specification unread — and organizes (1) the scope of the title and Claim 1, (2) the DB correction 'sole Theeuwes,' (3) the pharmacological-history meaning of Higuchi's contribution, and (4) the Cage-axis distance to modern microneedle patches / liposomal LNPs / mRNA-vaccine LNPs. Day 27 PH Open opening memo.

On May 30, 1978, three pharmacists at Bristol-Myers Co. (Edmund S. Granatek, Gerald M. Ziemba, Frederick L. Grab) filed US patent US4310515A 'Pharmaceutical compositions of cisplatin'. The compound itself — cis-diamminedichloridoplatinum(II), cis-Pt(NH₃)₂Cl₂ — had been synthesized in 1845 by Michele Peyrone and described in Liebigs Annalen der Chemie 51 as 'Peyrone's salt'. In 1893 Alfred Werner deduced its octahedral coordination structure. In 1965 Barnett Rosenberg at Michigan State University accidentally discovered, during electrolysis experiments, that the soluble platinum complex inhibited binary fission in E. coli, and in 1969 he reported antitumor activity in Nature 222 (385–386). Clinical trials began in 1971. But by 1978 the compound was 133 years old — long-public art, ineligible under the novelty requirement of 35 U.S.C. § 102. Bristol-Myers' Claim 1 instead covered an 'injectable, stable, sterile aqueous solution of cisplatin in a unit dosage form in a sealed container, at a concentration of 0.1 to 1.0 mg/mL and a pH in the range of 2.0 to 3.0.' This bypassed prior lyophilization-and-refrigeration practice and gave Bristol-Myers a room-temperature ready-to-use product. FDA approved the drug as Platinol on December 19, 1978 for testicular and ovarian cancers, and Bristol-Myers locked the 1980s cisplatin market through this formulation patent. This piece walks the five-layer IP stack — Peyrone 1845 / Werner 1893 / Rosenberg 1965 & 1969 / Research Corp's malonato platinum patent US4140707A (Cleare/Hoeschele/Rosenberg/Van Camp, priority 1972) / Bristol-Myers' formulation patent US4310515A (1978) — and records a heavy DB correction: the candidates.tsv number US4169726 actually points to General Electric's casting-alloy patent (Norman P. Fairbanks, 1977), entirely unrelated to cisplatin.

On May 11, 1945, microbiologist Andrew J. Moyer at the **USDA Northern Regional Research Laboratory** in Peoria, Illinois, filed U.S. Patent US2442141A 'Method for production of penicillin' as sole inventor, granted on May 25, 1948. The assignee is '**United States of America, as represented by the Secretary of Agriculture**'—the U.S. government (USDA representative). Claim 1 claims a method 'incubating a penicillin-producing mold in contact with an aqueous nutrient medium containing an assimilable carbon source 5–150 g/L and degraded proteinaceous material 5.0+ g/L, with carbon source added stepwise during the incubation period.' The specification **explicitly applies to both surface culture in Fernbach flasks and submerged state in tank fermenters**, and the application to agitated, aerated submerged culture in particular has historical significance as the WW2-era mass production technology. Alexander Fleming discovered the antibacterial action of *Penicillium notatum* in 1928, and Howard Florey/Ernst Chain/Norman Heatley established purification and therapeutic application at Oxford University in 1939–1941. But Florey sought U.S. support due to insufficient British production capacity, and visited the Peoria USDA Northern Lab with Heatley in July 1941. With Heatley's collaboration, Moyer (a) introduced **corn steep liquor**, a Peoria industrial byproduct of the time, as a nitrogen and growth-factor source, (b) used lactose as a carbon source, and (c) established submerged fermentation, increasing *Penicillium chrysogenum* productivity by **several hundred-fold**. This enabled the U.S. Army to secure 2.3 million doses of penicillin for the Normandy landings (D-Day) in June 1944, beginning the full-scale era of antibiotic medicine. This patent should be read as a **manufacturing-method patent** alongside the story 'Fleming/Florey/Chain did not patent the discovery,' and the British side criticized after the war that 'the U.S. took the patent and put us in a position of paying royalties' (in fact, USDA = U.S. government, not Moyer personally). This article excavates: (1) Claim 1 verbatim from US2442141A as obtained on Google Patents, (2) Florey/Heatley's Peoria visit in July 1941, (3) the three-element breakthrough of corn steep liquor + lactose + submerged fermentation, (4) the mass supply for D-Day in 1944, (5) the contrast between the Nobel Prize (1945 Fleming/Florey/Chain) and the patent, (6) the resonance with modern recombinant fermentation, antibody pharmaceuticals, and bioreactors. The DB (PH-009) description (USDA, Andrew J. Moyer, 1945 filing/1948 grant, Fleming did not patent but the manufacturing process was patented) is consistent with the primary source—the **3rd 'DB-agreement-confirmed' case** (after Day 11 aspirin and Day 12 norethindrone).

On June 20, 1990, three chemists at Pfizer Central Research (Sandwich research site) in the UK—Andrew S. Bell, David Brown, and Nicholas K. Terrett—established the priority date for U.S. Patent US5250534A 'Pyrazolopyrimidinone antianginal agents.' The patent claims a class of compounds with a **pyrazolo[4,3-d]pyrimidinone scaffold** as cGMP-PDE selective inhibitors. The specification includes as a specific example the compound later named sildenafil (UK-92,480, Viagra brand). The original target indications were **cardiovascular diseases such as angina pectoris, hypertension, and heart failure**, with the specification explicitly listing 'stable, unstable and variant (Prinzmetal) angina.' Within the cGMP-PDE inhibitor exploration program ongoing at Pfizer Sandwich since 1989, Nicholas Terrett led molecular design, and UK-92,480 was synthesized in 1989, with limited efficacy for angina found in initial clinical trials in 1991-1992. Side-effect observations (penile erection) in a small Phase I trial in 1992 began the indication switch to ED treatment, and on March 27, 1998, the FDA approved Viagra (sildenafil 25/50/100mg) as a treatment for **erectile dysfunction (ED)**. The DB row PH-006 in `~/ai-archaeology/db/candidates.tsv` lists 'Pfizer Inc., Peter Dunn / Albert Wood' / '1992' but Google Patents primary source confirms three errors: (a) Original Assignee is **Pfizer Corp SRL** (Pfizer's UK subsidiary), (b) inventors are **Andrew S. Bell / David Brown / Nicholas K. Terrett three co-inventors**, with Peter Dunn and Albert Wood **not listed in the inventor field of this patent**, (c) Priority date is **1990-06-20** (DB '1992' is the year of U.S. filing date 1992-05-14 only). Peter Dunn was a medicinal chemist at Pfizer Sandwich and may be listed as inventor on separate patents (later use patents or synthesis process improvement patents), but is absent from the body of US5250534A. Albert Wood was likely affiliated with the Pfizer Sandwich analytical chemistry team but is absent from the inventor field of this patent. In the consecutive DB-error correction series of Days 8/9/10/11, this is **the 10th case of DB-error discovery and correction** (after IC-009 Bluetooth, IC-011 CDMA, IC-012 RFID on Day 8; PH-003 PCR, PH-001 statin on Day 9; PH-004 monoclonal antibody, PH-002 insulin on Day 10; PH-007 captopril, PH-005 propranolol on Day 11).

On November 22, 1951, three researchers at Mexico's Syntex SA—Carl Djerassi (Austrian-born, emigrated to the U.S. under Nazi rule), Luis E. Miramontes (Mexican chemistry student, performed the actual synthesis), and George Rosenkranz (Hungarian-born, head of research at Syntex)—established the priority date for U.S. Patent US2744122A, 'delta 4-19-nor-17alpha-ethinylandrosten-17beta-ol-3-one and process.' Claim 1 encloses both the compound (a 17α-ethynyl-17β-ol-3-one in the 19-norandrostene series) and a six-step process: reduction of an estrone lower alkyl ether with alkali metal in liquid ammonia → mineral acid hydrolysis → chromic acid oxidation → selective formation of a 3-enol ether → treatment with acetylene in the presence of an alkali metal alkoxide → mineral acid hydrolysis. The core of this patent is **17α-ethynyl-19-nortestosterone (later named norethindrone / norethisterone)**, the first synthetic progestin to retain activity by oral administration. Russell Marker's 1944 establishment of mass progesterone synthesis from diosgenin obtained from wild yam *Dioscorea* in Veracruz, Mexico (later called the Marker degradation) created the research foundation for Syntex's founding (1944). Djerassi moved from the University of Wisconsin to Syntex in 1949 and led a steroid molecular-modification program. Miramontes recorded the first synthesis in his lab notebook on October 15, 1951 (now held by UNAM), consistent with the patent's priority date of 1951-11-22. In 1957 the FDA approved norethindrone for menstrual disorders; in 1960 Searle's norethynodrel (Frank Colton 1953 synthesis, Enovid brand) received FDA approval as an oral contraceptive, with Ortho-Novum (norethindrone-based) following. This article excavates: (1) Claim 1 verbatim from US2744122A as obtained on Google Patents, (2) the historical path from Marker degradation through the founding of Syntex SA and the Mexican steroid industry, (3) consistency between Miramontes's lab notebook of 1951-10-15 and the priority date of 1951-11-22, (4) the Djerassi vs. Miramontes credit problem (the patent cleanly lists three co-inventors, but the popular narrative tilts toward Djerassi), (5) parallel running of Searle's Frank Colton norethynodrel patent US2725389A, and (6) the resonance with modern low-dose pills, hormonal IUDs, ART, and hormone replacement therapy. After the consecutive DB error corrections in Days 8/9/10/11, this is the **rare case in which the DB description (Djerassi/Miramontes/Rosenkranz three co-inventors, Syntex Mexico City, 1951 synthesis, 1956 grant) matches the primary source**—the second 'DB-agreement-confirmed' case after Day 11's aspirin US644077A.

From the early 1960s, Imperial Chemical Industries (ICI) systematically explored β-adrenergic receptor blockers under James W. Black's research direction. After the first clinical candidate pronethalol (Alderlin, approved 1962, withdrawn 1963 for carcinogenicity), they reached propranolol (Inderal brand, UK approval 1965, US approval 1967). Propranolol's core patent is **US3337628A '3-naphthyloxy-2-hydroxypropylamines'** (priority 1962-11-23, filed 1963-11-12, granted 1967-08-22), inventors **Albert Frederick Crowther and Leslie Harold Smith** (assignee ICI). The DB-registered US3408387A 'Amidoaroxyalkanolamines' (priority 1964-09-30, filed 1965-09-17, granted 1968-10-29) was invented by **Ralph Howe and Leslie Harold Smith** and covers a **derivative series** within ICI's β-blocker exploration program. The DB row PH-005 lists 'Inventor: James W. Black,' but Black himself is **not named** on either patent — Black directed research as ICI's Research Director, while patent-filing work was handled by the chemists Crowther / Howe / Smith in a divided-labor structure. Black received the 1988 Nobel Prize in Physiology or Medicine ('important principles for drug treatment,' jointly evaluated with cimetidine H2 blocker work). Inventor-field corrections have occurred for four consecutive days (Day 8/9/10/11).

Squibb's Miguel A. Ondetti and David W. Cushman pursued angiotensin-converting enzyme (ACE) inhibitor molecular design from the early 1970s. The starting point was the bradykinin potentiating factor (BPF) peptides isolated by Brazilian São Paulo pharmacologist Sérgio H. Ferreira from the venom of Bothrops jararaca (jararaca pit viper) between 1965 and 1970. Squibb adopted a strategy to design orally active small-molecule ACE inhibitors using BPF peptides as templates, executing rational design in three stages: (1) Byers & Wolfenden's 1973 carboxypeptidase A model (zinc enzyme, substrate-structure analogy), (2) peptidomimetic design, and (3) sulfhydryl group (-SH) zinc coordination — arriving at SQ 14225 (later named captopril). The candidates DB row PH-007 lists 'Captopril patent US4046889A' with 'inventors Ondetti/Rubin/Cushman three co-inventors,' but the primary sources confirmed on Google Patents show: (a) US4046889A is 'Azetidine-2-carboxylic acid derivatives' with two inventors (Ondetti / Cushman), and (b) captopril's chemical backbone (proline + 3-mercaptopropanoyl linkage) is covered by US4105776A 'Proline derivatives and related compounds' (priority 1976-06-21, filed 1976-12-22, granted 1978-08-08, Ondetti/Cushman, Squibb). DB corrections have occurred for four consecutive days (Day 8/9/10/11). Read this as the 50-year reckoning between 1981 captopril FDA approval, 1985 Merck enalapril (second-generation ACE inhibitor), and modern AI-driven molecular design (AlphaFold / RoseTTAFold / structure-based drug design).

U.S. priority/filing January 12, 1923; granted October 9, 1923. Inventors: Frederick G. Banting, Charles H. Best, **and James B. Collip** as three co-inventors (the DB record listing only Banting/Best is incorrect). Original Assignee: University of Toronto **and** University of Alberta as joint assignees (the DB record listing UoT alone is also incorrect — Collip's share went to Alberta to reflect his university affiliation). Title: 'Extract obtainable from the mammalian pancreas or from the related glands in fishes, useful in the treatment of diabetes mellitus, and a method of preparing it.' Claim 1 defines a substance prepared from fresh pancreatic or related glands containing in concentrated form the extractive from the ductless portion of the gland, suitably free from injurious substances for repeated administration, with the physiological effect of reducing blood sugar useful for treating diabetes mellitus. Read this as the precursor to the 100-year reckoning between the legendary '$1 transfer' and the modern insulin pricing problem (US ~$300/vial vs Canada ~$30/vial, driven by recombinant analog insulins and PBM distribution structures, not by the 1923 patent). Title, full Claim 1, three inventors, filing/grant dates, and original/current assignees retrieved from Google Patents.

On August 7, 1975, Georges J. F. Köhler and César Milstein published 'Continuous cultures of fused cells secreting antibody of predefined specificity' in Nature (volume 256, issue 5517, pages 495-497), demonstrating monoclonal antibody production via continuous culture using the hybridoma method. Affiliation: **MRC Laboratory of Molecular Biology, Cambridge** — a Medical Research Council-operated research institute that is *not* part of Cambridge University (the DB record listing 'Cambridge University' is structurally inaccurate). Milstein wrote to the MRC proposing patenting, and the MRC replied: 'it is not immediately obvious what patentable features are at present disclosed in the Nature paper.' The UK NRDC (National Research Development Corporation) did not pursue patenting. On April 28, 1978, Hilary Koprowski and Carlo M. Croce of the Wistar Institute of Anatomy and Biology in the U.S. filed the **application patent US4172124A 'Method of producing tumor antibodies,'** granted October 23, 1979. The core invention (Nature paper) remained in the public domain; the application patent (tumor antibody production) was enclosed in the U.S. The 1980s UK industrial-policy debate, the 1984 Nobel Prize in Physiology or Medicine awarded to Jerne / Köhler / Milstein, and the 50-year reckoning with today's monoclonal antibody pharmaceutical market (over $200 billion annually as of 2024 — Herceptin, Keytruda, Humira, etc.).

Japanese priority June 7, 1974; U.S. filed December 4, 1975; granted September 20, 1977. Akira Endo, Masao Kuroda, Akira Terahara, Yoshio Tsujita, and Chihiro Tamura at Sankyo Co Ltd **jointly** invented the statin core patent US4049495A 'Physiologically active substances and fermentative process for producing the same.' The patent describes a fermentation process to obtain HMG-CoA reductase inhibitors ML-236A, ML-236B (later compactin / mevastatin), and ML-236C from the genus *Penicillium*. Verbatim Claim 1 text, title, five inventors, filing/priority/grant dates, and assignee retrieved from Google Patents. **The DB record (candidates.tsv) listing patent number US4231938 is wrong.** US4231938A is Merck's Lovastatin patent (MSD803, Monaghan/Alberts/Hoffman/Albers-Schonberg, filed 1979, granted 1980) — a different compound. The DB entries 'sole inventor,' 'discovered 1973, filed 1976' are also wrong. Read this as the precursor to the statin class (Mevacor / Pravachol / Zocor / Lipitor / Crestor) and modern coronary-disease prevention.

Filed in the U.S. on March 28, 1985; granted July 28, 1987. Norman Arnheim, Henry A. Erlich, Glenn T. Horn, Kary B. Mullis, Randall K. Saiki, and Stephen J. Scharf at Cetus Corporation **jointly** invented the PCR (Polymerase Chain Reaction) core patent US4683195A 'Process for amplifying, detecting, and/or-cloning nucleic acid sequences.' Mullis's standalone core-idea patent is the separate US4683202A; the Taq DNA polymerase implementation is US4965188A — three patents form one family. Roche acquired the Cetus PCR portfolio in 1991 (publicly reported around $300M initially, with subsequent licensing earning billions). Read this as the precursor to COVID-19 PCR testing, qPCR, digital PCR, CRISPR diagnostics (SHERLOCK / DETECTR), forensics, prenatal screening, and ancient DNA analysis. Title, six inventors, filing/grant dates, and assignee retrieved from Google Patents and WebSearch sources. Full text of Claim 1 and Description not yet verified verbatim. **The DB record (candidates.tsv) attributing this invention to 'Mullis himself' is inaccurate** — Mullis is one of six co-inventors; his sole-inventor patent is the separate US4683202A.